Article
Clinical factors predict metastatic progression post-RP
New Orleans--A combination of common clinical factors can accurately predict which patients who have biochemical failure after radical prostatectomy are likely to develop metastatic progression, said investigators from Memorial Sloan-Kettering Cancer Center, New York.
Related Videos
Adam Weiner, MD, on therapeutic decision-making in metastatic prostate cancer
Real-World Safety of Androgen Receptor Inhibitors in Nonmetastatic Castration-Resistant Prostate Cancer
Fred Saad, MD, FRCP, reacts to FDA approval of darolutamide in mCSPC
The Role of Bone-Targeted Therapies
Topline Results From Recent NMIBC Trials
Exploring Nadofaragene Firadenovec: Ongoing Trials and Study Designs
First-Line mHSPC Therapy: AR Inhibitors vs Chemotherapy
Professor Dickon Hayne shares data on mitomycin plus BCG in high-risk NMIBC
Thomas Powles, MBBS, MRCP, MD, on efficacy of sasanlimab plus BCG in BCG-naïve NMIBC
Using Ultrasensitive PSA Assays in Routine Practice
Related Content
